Enlivex Therapeutics (NASDAQ:ENLV) Releases Earnings Results, Misses Estimates By $0.07 EPS

Enlivex Therapeutics (NASDAQ:ENLV) issued its earnings results on Monday. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.07), Zacks reports.

Enlivex Therapeutics Stock Down 0.5 %

Enlivex Therapeutics stock traded down $0.01 during midday trading on Wednesday, reaching $0.95. The stock had a trading volume of 24,113 shares, compared to its average volume of 154,239. The firm has a market capitalization of $20.23 million, a PE ratio of -0.96 and a beta of 1.11. Enlivex Therapeutics has a 12 month low of $0.81 and a 12 month high of $4.59. The firm’s 50-day moving average price is $1.09 and its 200 day moving average price is $1.23.

Wall Street Analyst Weigh In

ENLV has been the subject of a number of recent research reports. D. Boral Capital restated a “buy” rating and set a $13.00 price target on shares of Enlivex Therapeutics in a research note on Monday, March 3rd. HC Wainwright upped their target price on shares of Enlivex Therapeutics from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Monday, March 24th.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.